KRAS and cancer: Direct targeting of mRNA of other RAS gene family members showed strong potential in regards of antitumor activity, leading to clinical trials of an mRNA-based cancer vaccine, an ASO, and two different siRNAs for targeting KRAS in cancer patients (ClinicalTrials.gov IDs: NCT03948763, NCT03101839, NCT01188785, NCT01676259 and NCT03608631).